Table 1 Survival parameters for three CDK4/6 inhibitors, Palbociclib, abemaciclib, and ribociclib combination therapies.

From: Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Strategies

PFS

OS

Best fitting

Survival parameters

Best fitting

Survival parameters

Palbociclib + fulvestrant

Lognormal

Meanlog = 2.2345763;

sdlog = 1.126612

Loglogistic

Shape = 1.762026;

scale = 32.63381

Abemaciclib + fulvestrant

Lognormal

Meanlog = 3.120524;

sdlog = 1.377591

Weibull

Shape = 1.38068;

scale = 60.06384

Ribociclib + fulvestrant

Lognormal

Meanlog = 2.579618;

sdlog = 1.327546

Loglogistic

Shape = 1.678677;

scale = 41.21087

  1. PFS progression free survival, OS overall survival.
Back to article page